The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
Screenshot of statistic data websites.
Follow the link and find Country Profiles in indonesian language on TB, Reproductive Health, Malaria, Lymphoma, Pneumonia, Hypertension and much more.
Alternative websites:
http://www.promkes.depkes.go.id/ or http://www.kemkes.go.id/
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
The meeting was held from 26 to 27 March 2018 to review and discuss the following topics:
Advances and challenges in the use of fTLC, and new approaches to detecting mycolactone using monoclonal antibodies (mAbs).
The status of development of rapid diagnostic tests (RDTs) targeting the M...UL_3720 protein.
The role of PCR as a reference test, and hurdles in providing a confirmatory diagnosis and in establishing a quality assurance programme.
New molecular tools with potential for implementation at a level lower than in the national or regional reference laboratory, such as loop-mediated isothermal amplification (LAMP) and recombinase polymerase amplification (RPA).
The need to harmonize and standardize methods for collection and preparation of specimens, so samples can be referred for diagnosis and stored for evaluation of new diagnostic tests in optimal conditions.
Barriers to accessing early diagnosis and treatment, including coordination at the programme level, and lack of adequate diagnostic tools.
Defining target product profiles (TPPs) to guide the development of new diagnostic tools that can be applied at different levels of the health system. Participants agreed that two TPPs would be developed to address the current gaps: (i) a rapid test for BU diagnosis at the primary health-care level; and (ii) a test for diagnosis of BU that can also assist in treatment monitoring and differential diagnosis at the district hospital or reference centre.
more
Chikungunya virus (CHIKV) is currently one of the most relevant arboviruses to public health. It is a member of the Togaviridae family and alphavirus genus and causes an arthritogenic disease known as chikungunya fever (CHIKF). It is characterized by a multifaceted disease, which is distinguished fr...om other arbovirus infections by the intense and debilitating arthralgia that can last for months or years in some individuals. Despite the great social and economic burden caused by CHIKV infection, there is no vaccine or specific antiviral drugs currently available. Recent outbreaks have shown a change in the severity profile of the disease in which atypical and severe manifestation lead to hundreds of deaths, reinforcing the necessity to understand the replication and pathogenesis processes. CHIKF is a complex disease resultant from the infection of a plethora of cell types. Although there are several in vivo models for studying CHIKV infection, none of them reproduces integrally the disease signature observed in humans, which is a challenge for vaccine and drug development. Therefore, understanding the potentials and limitations of the state-of-the-art experimental models is imperative to advance in the field. In this context, the present review outlines the present knowledge on CHIKV epidemiology, replication, pathogenesis, and immunity and also brings a critical perspective on the current in vitro and in vivo state-of-the-art experimental models of CHIKF.
more